12:56 PM
 | 
Jan 03, 2019
 |  BC Innovations  |  Emerging Company Profile

Auransa’s AI-predicted pipeline

How Auransa is using AI to uncover and treat new patient subgroups

Auransa Inc. has built a predictive AI-based discovery engine that analyzes patient-derived data to identify and develop the right compound for each patient subpopulation in less time than traditional discovery methods.

“The engine unbiasedly reveals the heterogeneity that is contained in a disease,” co-founder and CEO Pek Lum told BioCentury.

Auransa feeds its SubtypesMarkersTargetsRedefining (SMarTR) engine patient data from public databases, overlaying RNA, DNA and genotype data on top of clinical data, Lum said. Using several undisclosed machine learning techniques, the engine sifts through those data, clustering the information to detect patterns that translate into patient subpopulations. From those patterns, the engine uncovers disease subtypes and predicts targets, small molecule therapies and preclinical models for the subtypes.

Unlike conventional approaches that screen thousands of compounds with hit...

Read the full 617 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$100 USD
More Info >